ArticleThe Journal of pediatrics2018
The Need for Pediatric Drug Development.
Abstract read
In one paragraph
Article in The Journal of pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Enabling evidence generation for extremely preterm neonates: the use of neonatal real-world data.Pediatric research · 2026Review
- Promises, Pitfalls, and Paths Forward for the Pediatric Research Equity Act.JAMA health forum · 2026Article
- Six-Year Trends in Real-World Data Use for Post-Marketing Surveillance of New Medical Products in Japan.Clinical and translational science · 2026Review
- Impact of China's Drug Review and Approval System Reform on Pediatric Drugs: an Analysis Based on Registration Data from 2015 to 2024.Therapeutic innovation & regulatory science · 2025Article
- Understudied Populations in Radiation Exposure Research: Needs, Challenges, and Mitigation Strategies.Radiation research · 2025Article
- The Destructive Cycle in Bronchopulmonary Dysplasia: The Rationale for Systems Pharmacology Therapeutics.Antioxidants (Basel, Switzerland) · 2025Review
- Lack of formal regulatory definitions of off-label medication use in children: an analysis using agency inquiry and text mining.Frontiers in pharmacology · 2025Article
- Requirements and special considerations for drug trials with children across six jurisdictions: 1. Clinical trial application review in the regulatory approval process.Frontiers in medicine · 2025Article
- Paediatric Drug Development in China: Current Status and Future Prospects.Paediatric drugs · 2024Review
- Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals.World journal of methodology · 2024Review
- Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.Orphanet journal of rare diseases · 2024Review
- Off-Label Prescribing in Pediatric Population-Literature Review for 2012-2022.Pharmaceutics · 2023Review
- Diagnostic challenge: A pediatric patient with severe obesity and complications of imminent death.Obesity pillars · 2023Article
- Article
- Accelerating the Availability of Medications to Pediatric Patients by Optimizing the Use of Extrapolation of Efficacy.Therapeutic innovation & regulatory science · 2022Review
- Technical, Ethical, Legal, and Societal Challenges With Digital Twin Systems for the Management of Chronic Diseases in Children and Young People.Journal of medical Internet research · 2022Review
- Current situation of pediatric clinical trials in China: focus on trials for drug marketing application and administrative approval.BMC pediatrics · 2022Observational
- Opportunities and Challenges in Developing aACS infectious diseases · 2021Article
- COVID-19 and Treatment and Immunization of Children-The Time to Redefine Pediatric Age Groups is Here.Rambam Maimonides medical journal · 2021Review
- The Utility of Pharmacometric Models in Clinical Pharmacology Research in Infants.Current pharmacology reports · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Robert M WardDepartment of Pediatrics, University of Utah, School of Medicine, Salt Lake City, UT. Electronic address: Robert.ward@hsc.utah.edu.
Daniel K BenjaminDuke Clinical Research Institute, Duke University, Durham, NC.
Jonathan M DavisNeonatal Advisory Committee in the Office of the FDA Commissioner, Silver Spring, MD; Tufts University School of Medicine, Boston, MA.
Richard L Gorman
Ralph Kauffman
Gregory L KearnsDepartment of Pediatrics, Arkansas Children's Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR.
Mary Dianne Murphy
Catherine M T SherwinDepartment of Pediatrics, University of Utah, School of Medicine, Salt Lake City, UT.
Funding
Project-005U2COD023375 · OD · DUKE UNIVERSITY · PI Linda S Adair, Phillip Brian Smith · 2016 to 2026
$215.9MCOVID-19 Supplement - Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)U24TR001608 · NCATS · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2016 to 2022
$177.0MUtah Trial Innovation CenterU24TR001597 · NCATS · UNIVERSITY OF UTAH · PI DEAN, JONATHAN MICHAEL · 2016 to 2022
$39.6MTufts Clinical and Translational Research InstituteUL1TR001064 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2013 to 2017
$26.4MUNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5MPharmacogenomic and Metabolic Optimization of Glucocorticoid Therapy for AsthmaR01GM121648 · NIGMS · UNIVERSITY OF UTAH · PI REILLY, CHRISTOPHER A · 2017 to 2020
$2.5MPharmacometric Modeling of Immunosuppressants for Evaluation of Bioequivalence CriteriaU01FD005191 · FDA · UNIVERSITY OF UTAH · PI WARD, ROBERT MARSHALL · 2014 to 2017
$938kPharmacometric Modeling and Simulation for Evaluation of Bioequivalence for Leuprolide Acetate InjectionU01FD005442 · FDA · UNIVERSITY OF UTAH · PI WARD, ROBERT MARSHALL · 2015 to 2017
$600kEstablishing Risk in Neonatal Abstinence SyndromeR21DA041706 · NIDA · TUFTS MEDICAL CENTER · PI DAVIS, JONATHAN M., LESTER, BARRY M. · 2016 to 2017
$524kPeppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children with Functional Abdominal PainR21AT009101 · NCCIH · BAYLOR COLLEGE OF MEDICINE · PI SHULMAN, ROBERT J · 2016 to 2017
$436kArkansas Center for Advancing Pediatric Therapeutics (ArCAPT)UG1HD090876 · NICHD · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI JAMES, LAURA P, KEARNS, GREGORY LEE · 2016 to 2016
$69kFDA HHS R01 FD003899FDA HHS U01 FD005191FDA HHS U01 FD005442NCATS NIH HHS U24 TR001597NCATS NIH HHS U24 TR001608NCATS NIH HHS UL1 TR001064NCCIH NIH HHS R21 AT009101NICHD NIH HHS UG1 HD090876NIDA NIH HHS R21 DA041706NIGMS NIH HHS R01 GM121648NIGMS NIH HHS T32 GM086330NIH HHS U2C OD023375
Abstract
PubMed holds no abstract for this paper.
Indexed as
ChildClinical Trials as TopicDrug DevelopmentDrug LabelingGuidelines as TopicHumansPatient ParticipationPediatricsSulfanilamideThalidomideUnited StatesUnited States Food and Drug AdministrationSulfanilamideThalidomideBPCAInstitute for Advanced Clinical Trials for ChildrenInternational Neonatal Consortiumpediatric clinical trialspediatric pharmacologyPREA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.